Cholestyramine Resin
ApprovedSmall molecule
Cholestyramine Resin is one of 21 small molecule programs targeting Hyperphosphatemia. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Hyperphosphatemia
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Fosrenol
TakedaApproved
Renvela
SanofiPhase 3
Tums
OtsukaPhase 3
Sevelamer Hcl
NovartisApproved
Ibsrela
AArdelyx
Phase 3
Calcium-Based Phosphate Binder
SanofiApproved
Cholestyramine Resin
SSeoul National University Hospital
Approved
Nicotinic Acids
HHeidelberg University
Approved
MCI-196
Tanabe Pharma CorporationPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metformin1 trial
Hyperphosphatemia1 trial
Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
Completed·—·Phase 4·NCT05577507·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cholestyramine Resin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details